Bleeding is probably the major complication of anticoagulant treatment with vitamin K antagonists represented nowadays mostly by warfarin in the Czech Republic. The main risk factors in hemorrhagic complications of warfarinisation are the intensity and instability of the anticoagulant treatment, individual patient characteristics, warfarin interactions with other drugs and the length of the anticoagulant therapy. Severe bleeding in warfarin patients is most effectively brought about by a fast and complete undoing of the anticoagulation effect of the drug employing the prothrombin complex concentrate and slow i.v. vitamin K1 infusion regardless of the reason for the anticoagulation. This approach can secure the minimalisation of the bleeding's negative consequences. A less severe bleeding or asymptomatic increase in the international normalized ratio can be treated effectively by skipping or decreasing of the warfarin dosage and/or oral administration of vitamin K1 (i.v. administration only in selected higher risk cases) that does result only in a partial consolidation of coagulopathy but of such type that the risk of thrombotic event requires. The article's goal is to contribute to the treatment standardization in patients with warfarin overdose and/or with hemorrhagic complications due to warfarin treatment and it is available at www.thrombosis.cz. The guidelines include a ready-reference chart whose objective is immediate and quick crash course in the clinical practice.
Download full-text PDF |
Source |
---|
Arch Peru Cardiol Cir Cardiovasc
December 2024
Departamento de Medicina Interna, Sección de Cardiología Clínica, Universidad de Antioquia; Medellín, Colombia. Universidad de Antioquia Departamento de Medicina Interna Sección de Cardiología Clínica Universidad de Antioquia Medellín Colombia.
Objective: To determine the clinical, diagnostic, and therapeutic profile of patients with left intraventricular thrombus (LVT) in three high-complexity centers in Medellín, Colombia, between January 2000 and January 2022.
Materials And Methods: This was an observational and cross-sectional study that included 307 patients with LVT. Hospital records were analyzed to identify the clinical and therapeutic profile, and thrombus resolution and systemic embolism were evaluated.
Arch Peru Cardiol Cir Cardiovasc
December 2024
Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. Universidad San Ignacio de Loyola Vicerrectorado de Investigación Universidad San Ignacio de Loyola Lima Peru.
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition that can occur during the late pregnancy or puerperium. A 31-year-old woman with a recent twin pregnancy presented with heart failure symptoms nine days postpartum. On admission, she had volume overload and hemodynamic compromise, which was rapidly reversed with inotropic levosimendan support.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
School of Medicine; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Thromboembolic events are a common cause of morbidity and mortality in patients with cancer. While direct-acting oral anticoagulants (DOACs) have been established as the preferred agents of anticoagulation in most patients with cancer, data in resource-limited settings is limited.
Aims: The study aims to assess the comparative efficacy and safety of warfarin and rivaroxaban for cancer-associated thrombosis (CAT) in a resource-limited setting.
Cureus
December 2024
Intensive Care Medicine, St George Hospital, Sydney, AUS.
We report a case of an unusual polypharmacy overdose including warfarin in a patient with a metallic heart valve, complicated by the history that he had ceased taking anticoagulation in the preceding few months, that placed him in an initial prothrombotic phase during his presentation. Our case highlights the importance of elucidating all relevant clinical details in a polypharmacy overdose, as clearly and rapidly as feasible, to enable appropriate management.
View Article and Find Full Text PDFAims: This study aimed to determine the robustness, reproducibility and representativeness of the landmark Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (AF) (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF (ROCKET AF) randomised trials through replication in an observational AF patient registry.
Methods And Results: Patients from the Global Anticoagulant Registry in the FIELD (GARFIELD)-AF registry treated with apixaban, rivaroxaban or vitamin K antagonist (VKA) were assessed for eligibility for the ARISTOTLE and ROCKET AF trials. HRs of apixaban and rivaroxaban versus comparator for stroke/systemic embolism, major bleeding and all-cause mortality within 2 years follow-up were calculated using propensity score overlap-weighted Cox models.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!